TrialFind
SearchAbout
Saved trials

Filters

Sort by

Recruitment

Status

Phase

Age group

TrialFind

Making clinical research accessible to everyone. Search 500,000+ trials in plain English.

NavigationHomeSearch TrialsAboutSaved Trials
Data & LegalClinicalTrials.govPrivacyRegulatory infoContact

© 2025 TrialFind. Data sourced from ClinicalTrials.gov. Always consult a healthcare provider before enrolling.

CompletedPhase 4

The Feasibility of Florbetapir Quantitation in Europe

This study will evaluate whether the addition of quantitation as an adjunct to visual interpretations significantly improves the accuracy of Amyvid scan interpretation.

Leiden, Netherlands
View details
Active, not recruitingPhase 3

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determ

Birmingham, Alabama, United States+106 more
View details
Load more trials
CompletedPhase 1

A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease

The purpose of this study is determine whether a single IV dose of PF-04360365 is safe and well tolerated in Adults with Mild to Moderate Alzheimer's disease.

Heidelberg West, Victoria, Australia+11 more
View details
RecruitingN/A

Low-Intensity Focused Ultrasound (LIFU) Neuromodulation

This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with mild cognitive impairment ( MCI) due to Alzheimer's disease.

Morgantown, West Virginia, United States
View details
RecruitingN/A

Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation

The investigators will evaluate the theory that Alzheimer's disease-related memory impairment derives from the inefficient orchestration of rhythmic activity at the level of large-scale cortical networks. The results as expected to elucidat

Boston, Massachusetts, United States
View details
TerminatedPhase 3

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or previously treated

Tucson, Arizona, United States+80 more
View details
CompletedPhase 2

Bexarotene Amyloid Treatment for Alzheimer's Disease

Retinoid X receptors (RXR) are nuclear receptors that have been linked to numerous metabolic pathways relevant to Alzheimer's disease (AD) and Aβ (harmful protein) production and removal. The study drug "bexarotene" is an FDA approved anti-

Las Vegas, Nevada, United States
View details
Active, not recruitingPhase 2

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease

Carlsbad, California, United States+67 more
View details
TerminatedPhase 1

GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers

GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease. The current study is a single-blind, randomised, placebo-controlled, 4-cohort study to assess the safety, to

Harrow, Middlesex, United Kingdom
View details
UnknownPhase 1 / Phase 2

the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease

Evaluate the Safety and Efficacy of Exosomes Derived from Allogenic Adipose Mesenchymal Stem Cells（MSCs-Exos）in Subjects with Alzheimer's disease.

Shanghai, Shanghai Municipality, China
View details
TerminatedPhase 1

Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study

The purpose of this study is to identifying the intramuscular dose equivalent to the 4mg intravenous dose and assess its safety and tolerability as a weekly injection.

Los Angeles, California, United States
View details
WithdrawnPhase 2

Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Primary Objective: To compare the effect of repeat doses of Leukine to placebo administered subcutaneously (SC) on established cortical amyloid load in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD). Secondar

Houston, Texas, United States
View details
RecruitingPhase 3

Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)

This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia

Fuzhou, Fujian, China
View details
Not yet recruitingN/A

Yoga-based, Movement Therapy Device as Noninvasive Glymphatic Clearance Augmentation in Alzheimer's Disease.

This clinical trial evaluates a yoga-based intervention delivered through a powered therapeutic device designed to guide breathing and body movements. Building on evidence that mind-body practices may promote healthy aging, cognitive functi

Brno, Czechia+2 more
View details
Unknown

Gait Disorders in Patients With Cognitive Decline

The prevalence of neurodegenerative diseases will increase over the next decades driven by ageing population. It seems important to develop reliable, replicable and accessible diagnostic tools.

Strasbourg, France
View details
CompletedPhase 3

A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease

The purpose of this randomized, double-blind, active-controlled, flexible dosage, multicenter study is to evaluate the effectiveness and safety of galantamine tablet (16-24mg/day) for 16 weeks in the treatment of mild to moderate Alzheimer'

Multiple locations
View details
CompletedPhase 3

A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

The purpose of this study is to evaluate the safety and effectiveness of two doses of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease.

Multiple locations
View details
WithdrawnPhase 4

Improving Function, Quality of Life, Glycemia in Diabetics With Dementia

The primary purpose of this study is to determine if the study medication Methylphenidate (Ritalin) will improve subject's blood-sugar control by improving their motivation more than placebo. The secondary objectives of the study are to det

Multiple locations
View details
CompletedPhase 4

Antipsychotic Discontinuation in Alzheimer's Disease

In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established. AD patients with psychosis and/or agitation/aggression rec

Tuscaloosa, Alabama, United States+6 more
View details
Recruiting

Retinal Imaging in Neurodegenerative Disease

This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and

Durham, North Carolina, United States
View details